Drugs / LEO 90100
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01946386 | Sep → Oct 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01935869 | Aug → Nov 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02387853 | Mar 2016 → Mar 2018 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01536886 | May → Sep 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01347255 | May → Jun 2011 | psoriasis | LEO Pharma | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05919082 | Jun 2023 → Feb 2024 | psoriasis | LEO Pharma | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02416258 Comparator | Apr → Jun 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEO 90100 | “LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).” NCT01347255 ↗ |
| Route | Topical | “LEO 90100 cutaneous spray, ointment” NCT01347255 ↗ |